Karyopharm Therapeutics Inc (NAS:KPTI)
$ 0.93 -0.0427 (-4.39%) Market Cap: 115.89 Mil Enterprise Value: 143.75 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 73/100

Karyopharm Therapeutics Inc BOSTON Data Conference Call Transcript

May 29, 2020 / 05:00PM GMT
Release Date Price: $18.49 (-1.65%)
Operator

Good afternoon. My name is Dilem, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics Phase III BOSTON Study Results Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to Mr. Ian Karp, Karyopharm's Vice President, Investor and Public Relations. Please go ahead.

Ian Karp
Karyopharm Therapeutics Inc. - VP of Investor & Public Relations

Great. Thanks. And thank you all for joining us on today's conference call to discuss the results from the Phase III BOSTON study presented this morning at ASCO 2020. This is Ian Karp, and I'm joined today by Dr. Michael Kauffman, Chief Executive Officer; Dr. Jatin Shah, Chief Medical Officer; and Mr. John Demaree, Chief Commercial Officer.

On the call today, Dr. Kauffman will provide some general thoughts about the Phase III BOSTON trial results, and then Dr. Shah will review the key findings from the study, which were presented for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot